A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

ABSTRACT Background Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of nuclear proteins, including tumor suppressors, to the cytoplasm. Preclinical data suggest that the combination of SEL with checkpoint blockade may result in improved response to immunotherapy. Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Omar Alhalabi, Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bulent Yilmaz, Bettzy Stephen, Chinenye Lynette Ejezie, Justin Tyler Moyers, Serdar A. Gurses, Jeffrey How, Siqing Fu, Jordi Rodon, David S. Hong, Sarina A. Piha‐Paul, Vivek Subbiah, Ecaterina Elena Dumbrava, Daniel D. Karp, Filip Janku, Funda Meric‐Bernstam, Nizar M. Tannir, Aung Naing
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Cancer Medicine
Subjects:
immunotherapy
renal cell carcinoma
selinexor
Online Access:https://doi.org/10.1002/cam4.70280
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items